Aspect Imaging poised to bring neonatal MRI to EU

Baby picture
Aspect's neonatal MRI system doesn't need a safety zone or a radiofrequency shielded room, and so can be placed directly in the NICU.

Aspect Imaging earned a CE mark for its neonatal magnetic resonance imaging (MRI) device, which allows for the preparation and imaging of newborns inside the neonatal intensive care unit (NICU).

While regular MRI scanners may be used to image newborns, removing babies from the NICU for scanning can be risky. Unlike traditional MRI machines, the Embrace Neonatal MRI does not need a safety zone or a radiofrequency shielded room, so it may be placed in the NICU.

The system has an integrated, temperature-controlled incubator-like patient bed to minimize the infant's movement during scanning. It is indicated for the imaging of infants weighing from 1 kilogram to 4.5 kilograms, according to a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

 “Having a system in the neonatal intensive care enables safer imaging for this vulnerable patient population,” said Vasum Peiris, M.D., chief medical officer for the pediatrics and special populations at the FDA's Center for Devices and Radiological Health when the system scored FDA clearance in July.

RELATED: Visunex rounds up $20M for newborn eye imaging system

In addition to reducing risk to newborns who need imaging, the Embrace system allows medical staff easier access to infants during scanning. The device’s design also allows intubated infants to be scanned without disconnecting the tubing.

“We’re thrilled to finally have CE marking for our Embrace system, so that we can continue to reach and help the most vulnerable population of all—premature babies,” said Aspect CEO said Uri Rapoport, in the statement. “Our technology will be able to assist neonatologists with their clinical diagnoses in the NICU, and improve neonatal care where it will be used.”

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.